Table 4.

Myosteatosis, neutrophil‐to‐lymphocyte ratio, and survival from date of treatment start

	Progression‐free survival				Overall survival
	No myosteatosis		Myosteatosis		No myosteatosis		Myosteatosis
	NLR < 2.8	NLR > 2.8	NLR < 2.8	NLR > 2.8	NLR < 2.8	NLR > 2.8	NLR < 2.8	NLR > 2.8
#Events/at risk	29/34	15/17	26/44	27/28	27/34	14/17	26/44	23/28
Median (mo)	4.4	3.9	24.0	8.4	9.8	10.1	30.8	10.4
HR	1.328		0.469		1.178		0.388
95% CI	0.698‐2.526		0.259‐0.851		0.611‐2.270		0.208‐0.724
P	.388		.013		.625		.003

Cox model adjusted for age (continuous), weight loss (<5%, 5‐9.9, or >9), BMI (<18.5, 18.5‐24.9, 25‐30, or >30), and ECOG (0, 1, or 2).

Abbreviations: BMI, body mass index; ECOG, Eastern Cooperative Oncology Group Performance; NLR, neutrophil‐to‐lymphocyte ratio.